Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BridgeBio Pharma stock

Own BridgeBio Pharma stock in just a few minutes.

BridgeBio Pharma, Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 385 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in BridgeBio Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BridgeBio Pharma share price

Use our graph to track the performance of BBIO stocks over time.

BridgeBio Pharma shares at a glance

Information last updated 2021-04-30.
52-week range$26.17 - $73.50
50-day moving average $59.85
200-day moving average $57.38
Wall St. target price$84.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-10.90

Buy BridgeBio Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BridgeBio Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BridgeBio Pharma financials

Revenue TTM $8.2 million
Gross profit TTM $8.2 million
Return on assets TTM -44.42%
Return on equity TTM -173.15%
Profit margin 0%
Book value $3.92
Market capitalisation $8.3 billion

TTM: trailing 12 months

Shorting BridgeBio Pharma shares

There are currently 10.7 million BridgeBio Pharma shares held short by investors – that's known as BridgeBio Pharma's "short interest". This figure is 2% up from 10.5 million last month.

There are a few different ways that this level of interest in shorting BridgeBio Pharma shares can be evaluated.

BridgeBio Pharma's "short interest ratio" (SIR)

BridgeBio Pharma's "short interest ratio" (SIR) is the quantity of BridgeBio Pharma shares currently shorted divided by the average quantity of BridgeBio Pharma shares traded daily (recently around 813663.65019011). BridgeBio Pharma's SIR currently stands at 13.15. In other words for every 100,000 BridgeBio Pharma shares traded daily on the market, roughly 13150 shares are currently held short.

However BridgeBio Pharma's short interest can also be evaluated against the total number of BridgeBio Pharma shares, or, against the total number of tradable BridgeBio Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BridgeBio Pharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 BridgeBio Pharma shares in existence, roughly 70 shares are currently held short) or 0.138% of the tradable shares (for every 100,000 tradable BridgeBio Pharma shares, roughly 138 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against BridgeBio Pharma.

Find out more about how you can short BridgeBio Pharma stock.

BridgeBio Pharma share dividends

We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.

BridgeBio Pharma overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site